Popular terms

Cirrhosis topics
Hypertension
Vascular Disease
Endothelial Dysfunction
Endothelial
Dysfunction
Cardiovascular Disease
Cardiovascular
Hepatocellular Carcinoma
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Nephropathy
Nucleic Acid
Inflammation
Recombinant
Wound Healing

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cirrhosis patents



      

This page is updated frequently with new Cirrhosis-related patent applications.




Date/App# patent app List of recent Cirrhosis-related patents
07/14/16
20160202274 
 Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers patent thumbnailClinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The Unversity Of Oxford


07/14/16
20160200798 
 Novel means and methods for treating hbv infection and associated conditions patent thumbnailNovel means and methods for treating hbv infection and associated conditions
The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (cdrs) configured to bind a first antigen; and (b) (ba) a second set of six cdrs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from hepatitis b virus (hbv) small surface antigen; hbv medium surface antigen; and hbv large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (nk) cells and cytotoxic t lymphocytes (ctls). Also provided are compositions for use in a method of treating or preventing hbv infection and/or a condition caused by said hbv infection, said condition caused by said hbv infection being selected from liver cirrhosis and hepatocellular carcinoma..
Deutsches Krebsforschungszentrum


07/07/16
20160193169 
 Compositions and methods for treating intestinal hyperpermeability patent thumbnailCompositions and methods for treating intestinal hyperpermeability
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

06/16/16
20160166539 
 A novel composition for nonalcoholic fatty liver disease (nafld) patent thumbnailA novel composition for nonalcoholic fatty liver disease (nafld)
The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited


06/02/16
20160151420 
 Composition for preventing and treating liver fibrosis or liver cirrhosis, containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells patent thumbnailComposition for preventing and treating liver fibrosis or liver cirrhosis, containing, as active ingredient, mesenchymal stem cells derived from human embryonic stem cells
The present invention relates to a composition for preventing and/or treating liver fibrosis or liver cirrhosis, which contains, as an active ingredient, mesenchymal stem cells derived from human embryonic stem cells. In the present invention, it was confirmed that mesenchymal stem cells derived from human embryonic stem cells have a preventive effect against liver fibrosis.
Seoul National University Hospital


05/05/16
20160122386 
 V1a receptor agonists patent thumbnailV1a receptor agonists
Compounds of formula (i), salts thereof, and compositions and uses thereof are described. The compounds are useful as v1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, hrs2 and refractory ascites..
Ferring B.v.


05/05/16
20160120938 
 P2x7 receptor agonist for use in preventing or treating kidney injury patent thumbnailP2x7 receptor agonist for use in preventing or treating kidney injury
The present invention relates to the treatment or prevention of kidney injury and in particular acute kidney injury, such as acute kidney injury associated with cirrhosis. The invention relates to the treatment or prevention of such injury by administration of an agonist of the p2x7 receptor..
Ucl Business Plc


05/05/16
20160120839 
 Compositions and methods for the treatment of inflammatory bowel disease patent thumbnailCompositions and methods for the treatment of inflammatory bowel disease
The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited


05/05/16
20160120838 
 Compositions and methods for the treatment of inflammatory bowel disease patent thumbnailCompositions and methods for the treatment of inflammatory bowel disease
The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

04/21/16
20160106770 
 Epigenetic mechanisms of anti-fibrotic action for the liver patent thumbnailEpigenetic mechanisms of anti-fibrotic action for the liver
This invention demonstrates the therapeutic efficacy of yang-gan-wan (ygw) and its active components, especially in the formulation provided by sheng-pu pharmaceutials, inc., for treating and preventing liver fibrosis. This invention further demonstrates mecp2 is an important therapeutic target for ygw and its active ingredients' action against liver fibrosis and cirrhosis..

03/24/16
20160084849 

Biomarker composite test for hepatic vein pressure gradient and cirrhosis treatment


Diagnostic biomarker panel, method, kit, and device for diagnosing the severity and/or prognosis of cirrhosis are provided. More specifically, the invention provides a novel biomarker panel correlating to hvpg and esophageal varices.
The Regents Of The University Of California


03/17/16
20160077109 

Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers


The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The University Of Oxford


03/10/16
20160068890 

Gene signatures of inflammatory disorders that relate to the liver


This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (crohn's and ulcerative colitis).
Institut National De La Recherche Agronomique


03/03/16
20160058785 

Galactose-pronged polysaccharides in a formulation for antifibrotic therapies


Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-pdgf receptors; (ii) synaptophysin; (iii) zvegf3; (iv) ccr1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases mmp 2 and mmp9; (viii) matrix metalloproteinase inhibitors timp1 and tmp2; (ix) integrins; (x) tfg-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.. .
Galectin Therapeutics, Inc.


02/04/16
20160031858 

Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing dicarboxylic acid bisamide derivatives


Or pharmaceutically acceptable salts thereof, which are able to form complexes with or chelate metal ions. The invention also relates to the use of said compounds as an agent for the prevention and/or treatment of cardiovascular, viral, cancer, neurodegenerative and inflammatory diseases, diabetes, age-related diseases, diseases caused by microbial toxins, alcoholism and alcoholic cirrhosis, anaemia, porphyria cutanea tarda, and transition metal salt poisoning.

02/04/16
20160031810 

Benzidine derivative, preparing same, and pharmaceutical composition containing benzidine derivative for treating liver disease caused by hepatitis c virus


The disclosed compounds have antiviral activity against c-type virus, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating liver disease caused by hepatitis c virus. The benzidine derivative according to the present invention has excellent antiviral activity against hepatitis c virus and exhibits excellent medicinal activity in the living body, and thus the pharmaceutical composition containing the same as an active ingredient can be useful as a pharmaceutical composition for preventing or treating liver disease, such as acute hepatitis c, chronic hepatitis c, cirrhosis, or hepatocellular carcinoma, caused by c-type virus..
Seoul National University R&db Foundation


01/28/16
20160022776 

Trail receptor agonists for treatment of fibrotic disease


Pro-apoptotic agents such as ligands and agonists of agonistic trail receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (hscs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (pscs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells.
Theraly Pharmaceuticals, Inc.


01/21/16
20160015422 

Devices and methods for intrahepatic shunts


The invention provides methods and devices for treating liver cirrhosis or portal hypertension by creating an intrahepatic shunt, or new passage, from a portal vein of a patient to a hepatic vein using a device with intravascular imaging capabilities and pressure sensing capabilities or positioning mechanisms. The integration of intravascular imaging aids in the precise placement of the shunt and pressure measurement may verify successful shunt creation.
Volcano Corporation


12/24/15
20150368188 

Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis


The present invention relates to compounds of the formula i and in particular medicaments comprising at least one compound of the formula i for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which adamts5 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.. .
Merck Patent Gmbh


12/17/15
20150361176 

Ligands that bind tgf-beta receptor ii


The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.
Glaxo Group Limited


11/26/15
20150336966 

Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders


The present invention relates to certain substituted tricyclic acid derivatives of formula (i) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer..
Arena Pharmaceuticals, Inc.


11/05/15
20150313946 

Methods modulating immunoregulatory effect of stem cells


The present invention provides methods or kits with inflammatory cytokines to pretreat 1-iscs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, parkinson's disease, chronic infections, and gvhd. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (jvfscs)..
Rutgers, The State University Of New Jersey


10/08/15
20150283127 

Saquinavir-no for immunomodulation


The nitric ester of saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, i useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, guillain barré syndrome, hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematous, type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis..

08/20/15
20150232943 

Methods of diagnosing liver cancer in a subject and a kit for diagnosing liver cancer


Disclosed are methods of diagnosing liver cancer in a subject as well as methods of assessing the risk of a subject having chronic hepatitis and liver cirrhosis of developing liver cancer. Also disclosed are kits for the diagnosis of liver cancer..
Singapore Health Services Pte Ltd


08/13/15
20150225369 

Ddr2 inhibitors for the treatment of osteoarthritis


The present invention relates to compounds of the formula i and in particular medicaments comprising at least one compound of the formula i for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which ddr2 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.. .
Merck Patent Gmbh


08/13/15
20150224106 

Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and/or salt thereof for improving liver functioning


A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.


08/06/15
20150219664 

Methods and compositions for diagnosis of inflammatory liver disease


The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (e3) levels, either alone or with levels of eotaxin-1 (e1), and optionally, with levels of ccl22 and, further optionally, with levels of il15.
Medizinische Hochschule Hannover


08/06/15
20150216827 

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

07/02/15
20150182572 

Plant extract and the process for treating hepatic fibrosis and liver cancer


An extract of graptopetalum paraguayense prepared by a method that includes: extracting a graptopetalum paraguayense (gp) starting material with an alcoholic solvent to produce an alcoholic extract and a residue; separating the residue from the alcoholic extract; extracting the residue with an aqueous dimethyl sulfoxide (dmso) solvent to produce a dmso extract; subjecting the dmso extract to ultrafiltration using a filter having a selected molecular weight cutoff; drying a fraction retained by the filter to obtain the extract of graptopetalum paraguayense. Uses of an extract of graptopetalum paraguayense for the treatment or prevention of liver fibrosis, hepatic cirrhosis, liver cancer, recurrence of liver fibrosis after surgery, or recurrence of liver cancer after surgery..
Development Center For Biotechnology


07/02/15
20150181844 

Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof


Described herein is the generation of fah+/− heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing fah−/− homozygote pigs. The fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma..
Mayo Foundation For Medical Education And Research


06/25/15
20150174103 

Urea compounds and their use as enzyme inhibitors


Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

06/18/15
20150168426 

Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension


The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (cd31+/41−), pan-leukocyte (cd11a+), lymphocyte (cd4+), erythrocyte (cd235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.. .
Assistance Publique - Hopitaux De Paris


06/04/15
20150150897 

Methods of treating hepatitis c virus infection in subjects with cirrhosis


Methods of treating hepatitis c virus infection in a subject with cirrhosis comprising administering to the subject an effective amount of compound 1.. .
Gilead Pharmasset Llc


05/28/15
20150148658 

Method for the detection and staging of liver fibrosis from image acquired data


This invention relates to methods for ascertaining at least one of liver fibrosis or cirrhosis in a subject, by processing of one or more medical images of the liver, using a computing machine, to quantify nodularity of the surface of the liver and calculate a liver surface nodularity score.. .
University Of Mississippi Medical Center


05/21/15
20150141501 

Ultrapure tetrahydrocannabinol-11-oic acids


This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.. .
Corbus Pharmaceutics Inc.


05/14/15
20150132370 

Composition and methods for reduced scarring and treatment of fibrosis


Embodiments of the present disclosure are directed to methods of treating, reducing or preventing fibrosis or scarring including administering a therapeutic molecular agent selected from the group consisting of an agent that inhibits chaperonin containing t-complex polypeptide subunit eta polypeptide (“cct-eta”), an agent that inhibits α-smooth muscle actin (“α-sma”), or a combination thereof. In embodiments, the fibrosis may include dupuytren's contracture, peyronie's disease, pulmonary fibrosis, cirrhosis, interstitial lung disease or scarring alopecia..

05/14/15
20150132289 

Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy


A method or composition comprising an anti-cd3 immune molecule for treatment of psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) in a subject.. .

05/07/15
20150126432 

V1a receptor agonists


Compounds of formula (i), salts thereof, and compositions and uses thereof are described. The compounds are useful as v1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, hrs2 and refractory ascites..
Ferring B.v.


04/23/15
20150111937 

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

04/23/15
20150111878 

Compositions and methods for treating intestinal hyperpermeability


The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.. .

04/16/15
20150105293 

Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers


The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis.
The Chancellor, Masters And Scholars Of The University Of Oxford


04/09/15
20150098926 

Methods of treating hepatitis c virus infection


The present invention provides methods of treating hepatitis c virus (hcv) infection; methods of reducing the incidence of complications associated with hcv and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from hcv infection. Also provided are methods of treating liver steatosis and liver fibrosis..
The J. David Gladstone Institutes


04/02/15
20150094277 

Combination therapy and methods for treatment and prevention of hyperproliferative diseases


The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as hiv-aids, hepatitis b, hepatitis c and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects.

03/26/15
20150087639 

Nitrogenous heterocyclic derivatives and their application in drugs


The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis..
Sunshine Lake Pharma Co., Ltd.


02/26/15
20150057170 

Method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens


Methods and compositions are described for the diagnosis of primary biliary cirrhosis. Novel autoantigens are described for use in assays which employ test samples from individuals..
Massachusetts General Hospital


01/29/15
20150031771 

Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin


There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis..
Korea Institute Of Ocean Science And Technology


01/29/15
20150031027 

Use of saa1 beta/beta homozygote in the prognosis diagnosis and diagnosis of liver cirrhosis


Provided is uses of saa1β/β(1.5/1.5) homozygote in prognosis and/diagnosis of liver cirrhosis, and in preparation of a reagent for liver cirrhosis prognosis and/or liver cirrhosis diagnosis. Recognition of liver cirrhosis susceptible populations can be achieved by detection of human saa1β/β homozygote and non-saa1β/β homozygote through real-time fluorescence quantitative allele specific pcr..

01/15/15
20150018299 

Treatment of liver conditions


The present disclosure concerns the a3 adenosine receptor agonist, 2-chloro-n6-(3-iodobenzyl)-adenosine-5′-n-methyluronamide (cl-ib-meca) in an amount of at least about 10 mg/day, for use in treatment of hepatocellular carcinoma (hcc). The present invention also provides cl-ib-meca for use in maintenance of liver function in a subject having a chronic liver disease, such as cirrhosis.
Can-fite Biopharma Ltd.


12/04/14
20140357733 

Methods relating to identification of susceptibility to liver injury


The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of ppar-γ and tgfβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources.

11/06/14
20140329900 

Small molecule inhibitors of stat3 with anti-tumor activity


The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.

11/06/14
20140329747 

Compositions and methods for treating renal failure


The present disclosure relates to the use of angiotensin ii in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.. .

09/18/14
20140271954 

Toxin expelling powder comprising root of buckwheat and preparation process thereof


The present invention provides tartary buckwheat detox powder and a method for preparing the same. Raw materials are loveyly hemsleya root, sophora flavescens root, tartary buckwheat and dried ginger.

09/04/14
20140249209 

Methods for the treatment and prevention of liver disease


The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (hnf4α; also known as nr2a1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.. .

08/21/14
20140234288 

Lysosomal acid lipase therapy for nafld and related diseases


The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.

08/07/14
20140221350 

Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists


The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..

07/10/14
20140193431 

Anti-c-met antibody having hgf activity and use thereof


Disclosed are a human antibody comprising a human complementarity-determining region (cdr), which binds specifically to c-met, and a framework region (fr), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody b7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-met-specific human antibody can function as an hgf mimic that can be used as a wound healing composition.

07/03/14
20140187633 

Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis


In various embodiments, the present invention provides methods of treating and/or preventing nash and/or pbc comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .

07/03/14
20140187504 

Prevention and treatment of inflammatory conditions


The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ald). More specifically the present embodiments relate to the prevention and treatment of ald through the administration of an retinoic acid receptor (rar) agonist.

06/26/14
20140179726 

Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction


A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. A human) to physiological processes within the host.

06/12/14
20140162286 

Method for the detection of enzymatic activity with magnetically functionalized substrates


The present invention provides methods for detecting an enzymatic activity, the method including combining at least one magnetic particle to an enzyme substrate to form a magnetically modified substrate, reacting the magnetically modified substrate with at least one enzyme; and detecting a change in a magnetic property of the magnetically modified substrate or its cleavage products, thereby detecting an activity of said at least one enzyme, wherein the method may be applied to a human subject to detect a disease selected from the group consisting of rheumatitis, arthritis, an injury, dupuytren's disease, peyronie's disease, a collagen related disease, steatosis, fibrosis, cirrhosis, metastasis, tissue regeneration, cancer, coronary disease, a liver disease, a metabolic condition, an infection and an inflammatory disease.. .

05/15/14
20140134751 

Diagnostic method


Disclosed herein is a method for diagnosing hepatic cancer by analysing a sample and determining the level of at least one compound selected from the group consisting of glycine, trimethylamine-n-oxide, hippurate and citrate and comparing the levels in the sample with control levels. The analysis of the sample can involve the determination of a profile for the sample.

03/27/14
20140086984 

Pharmaceutical use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof


The present invention provides a new use of 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and pharmaceutically acceptable salt or derivative thereof. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including mmps and timps, and so it can inhibit liver fibrosis.

03/13/14
20140073606 

2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections


The present invention relates to 2′-fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including hepatitis b virus (hbv) and secondary disease states and conditions thereof (cirrhosis and liver cancer), heptatitis c virus (hcv), herpes simplex virus i and ii (hsv-1 and hsv-2), cytomegalovirus (cmv), varicella-zoster virus (vzv) and epstein barr virus (ebv) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially hbv.. .

02/13/14
20140045718 

Biomarkers for inflammation of the liver


The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver.; the proteins are selected from the group of er6q, vimentin, actin alpha 1 skeletal muscle protein, hmfap 4, tropomyosin, ptges 2, amyloid p component, transgelin, calponin 1, homo sapiens p20 protein, 17 kda myosin light chain, h chain h igg b12, prolyl 4-hydroxylase, beta subunit methylenetetrahydrofolate dehydrogenase 1, pro2619, aldehyde dehydrogenase 1, fibrinogen alpha chain preproprotein, fructose-bisphosphate aldolase b, argininosuccinate synthetase, eefla2, at p 5 al, alpha-2 actin, regucalcin, serum albumin, mitochondrial malate dehydrogenase, mitochondrial acetoacetyl-coa thiolase or in each case a partial sequence thereof.. .

12/19/13
20130337055 

Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection


The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including hepatitis b and hepatitis c viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions..

11/21/13
20130309202 

Methods for improving liver function


The present invention provides methods to improve liver function utilizing tocotrienols. In particular, various liver pathologies may be treated using the present methods, including cirrhosis, hepatitis, and sclerosing cholangtitis.

11/14/13
20130302335 

Ligands that bind tgf-beta receptor ii


The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.



Cirrhosis topics: Hypertension, Vascular Disease, Endothelial Dysfunction, Endothelial, Dysfunction, Cardiovascular Disease, Cardiovascular, Hepatocellular Carcinoma, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Nephropathy, Nucleic Acid, Inflammation, Recombinant, Wound Healing

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cirrhosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cirrhosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5006

4782

2 - 1 - 101